denosumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
denosumab: clinical details
Prescribing considerations
- Confirm the licensed indication and corresponding formulation.
- Correct hypocalcaemia and assess calcium and vitamin D intake before initiation.
- Assess oral health and jaw-necrosis risk; consider preventive dentistry when risk factors are present.
- Plan continuity or an appropriate transition before stopping osteoporosis treatment because rebound bone loss and multiple vertebral fractures may occur.
- The osteoporosis formulation should not be used in people younger than 18 years; oncology use in adolescents is restricted to skeletally mature patients with the licensed tumour indication.
- Record the brand and batch number for biological-product traceability.
Contraindications and cautions
- Both selected products: hypersensitivity to denosumab or an excipient.
- Obodence: hypocalcaemia.
- Osenvelt: severe untreated hypocalcaemia and unhealed lesions following dental or oral surgery.
Monitoring
- Check calcium before treatment and whenever symptoms suggest hypocalcaemia.
- For the osteoporosis formulation, check calcium before each administration and after initial treatment in patients predisposed to hypocalcaemia.
- For the oncology formulation, check calcium before initial administration, within two weeks afterwards and more often when risk factors are present.
- Increase vigilance in severe renal impairment or dialysis; no renal dose adjustment is specified, but hypocalcaemia risk rises substantially.
- Monitor oral symptoms, new thigh or groin pain and persistent ear symptoms.
- After stopping treatment for giant cell tumour of bone, monitor for symptomatic rebound hypercalcaemia and reassess supplementation.
Clinical pharmacology
Denosumab is a recombinant human IgG2 monoclonal antibody targeting RANKL. Blocking RANK signalling suppresses osteoclast development, function and survival, reducing cortical and trabecular bone resorption.
Formulation and product differences
- Obodence is a single-use pre-filled syringe licensed for adult osteoporosis and specified causes of bone loss; an appropriately trained person may administer it.
- Osenvelt is a single-use vial licensed for skeletal complications of advanced malignancy and selected giant cell tumours of bone; a healthcare professional must administer it.
- Both require refrigerated, light-protected storage and must not be frozen or shaken, but their excipients and permitted room-temperature storage conditions differ.
denosumab preparations and strengths
Injection
Route: Parenteral
Strengths: 60 mg, 60 mg/mL, 120 mg
denosumab interactions
Duplicate bone-resorption treatment and medicines that increase hypocalcaemia or jaw-necrosis risk require attention.
Other denosumab-containing products
Do not use concurrently because this duplicates the same active treatment.
Bisphosphonates
The cancer and giant-cell-tumour formulation should not be given concurrently with a bisphosphonate.
Systemic corticosteroids
They may add to hypocalcaemia and osteonecrosis-of-the-jaw risk, so stronger risk assessment and monitoring may be needed.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.